CY1116399T1 - Πυραζολυλαμινοπυριδινες ως αναστολεις της fak - Google Patents

Πυραζολυλαμινοπυριδινες ως αναστολεις της fak

Info

Publication number
CY1116399T1
CY1116399T1 CY20151100462T CY151100462T CY1116399T1 CY 1116399 T1 CY1116399 T1 CY 1116399T1 CY 20151100462 T CY20151100462 T CY 20151100462T CY 151100462 T CY151100462 T CY 151100462T CY 1116399 T1 CY1116399 T1 CY 1116399T1
Authority
CY
Cyprus
Prior art keywords
pyrazylylamin
pyrides
fak inhibitors
present
fak
Prior art date
Application number
CY20151100462T
Other languages
English (en)
Inventor
Jerry Leroy Adams
Thomas H Faitg
Neil W Johnson
Hong Lin
Jiri Kasparec
Mark Mellinger
Ren Xie
Xin Peng
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42132177&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116399(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CY1116399T1 publication Critical patent/CY1116399T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung

Abstract

Η παρούσα εφεύρεση σχετίζεται με μία ένωση του τύπου (I) ή ένα φαρμακευτικώς αποδεκτό άλας αυτής, όπου R1, R2, R3, R12, R13, Q, Ζ και p είναι όπως περιγράφονται στο παρόν. Ενώσεις της παρούσας εφεύρεσης είναι χρήσιμες για την αντιμετώπιση καρκίνων.
CY20151100462T 2008-10-27 2015-05-22 Πυραζολυλαμινοπυριδινες ως αναστολεις της fak CY1116399T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10856808P 2008-10-27 2008-10-27
US17851709P 2009-05-15 2009-05-15
US24243209P 2009-09-15 2009-09-15
EP20090829580 EP2421537B1 (en) 2008-10-27 2009-10-27 Pyrazolylaminopyridines as inhibitors of fak

Publications (1)

Publication Number Publication Date
CY1116399T1 true CY1116399T1 (el) 2017-02-08

Family

ID=42132177

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100462T CY1116399T1 (el) 2008-10-27 2015-05-22 Πυραζολυλαμινοπυριδινες ως αναστολεις της fak

Country Status (36)

Country Link
US (6) US20110207743A1 (el)
EP (1) EP2421537B1 (el)
JP (1) JP5642689B2 (el)
KR (1) KR101512217B1 (el)
CN (1) CN102264371B (el)
AR (1) AR073993A1 (el)
AU (1) AU2009320144B2 (el)
BR (1) BRPI0920053B8 (el)
CA (1) CA2741760C (el)
CL (1) CL2011000933A1 (el)
CO (1) CO6361929A2 (el)
CR (1) CR20110264A (el)
CY (1) CY1116399T1 (el)
DK (1) DK2421537T3 (el)
DO (1) DOP2011000113A (el)
EA (1) EA021927B1 (el)
ES (1) ES2539835T3 (el)
HK (1) HK1161680A1 (el)
HR (1) HRP20150531T1 (el)
IL (1) IL212444A (el)
JO (1) JO3067B1 (el)
MA (1) MA32727B1 (el)
MX (1) MX2011004369A (el)
MY (1) MY161890A (el)
NZ (1) NZ592477A (el)
PE (1) PE20110941A1 (el)
PL (1) PL2421537T3 (el)
PT (1) PT2421537E (el)
RS (1) RS54045B1 (el)
SG (1) SG195608A1 (el)
SI (1) SI2421537T1 (el)
SM (1) SMT201500157B (el)
TW (1) TWI454467B (el)
UY (1) UY32200A (el)
WO (1) WO2010062578A1 (el)
ZA (1) ZA201102892B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
BR112013018565A2 (pt) * 2011-01-26 2016-09-27 Univ Texas combinações
EP2675794B1 (en) 2011-02-17 2019-02-13 Cancer Therapeutics Crc Pty Limited Selective fak inhibitors
CA2827171C (en) 2011-02-17 2019-04-09 Cancer Therapeutics Crc Pty Limited Fak inhibitors
CA2840211A1 (en) * 2011-06-28 2013-01-03 Glaxosmithkline Intellectual Property (No.2) Limited Method of administration and treatment
US10106834B2 (en) 2013-10-09 2018-10-23 The General Hospital Corporation Methods of diagnosing and treating B cell acute lymphoblastic leukemia
WO2017004192A1 (en) 2015-06-29 2017-01-05 Verastem, Inc. Therapeutic compositions, combinations, and methods of use
CN108948019B (zh) * 2017-05-18 2022-07-08 广东东阳光药业有限公司 黏着斑激酶抑制剂及其用途
WO2019117813A1 (en) * 2017-12-15 2019-06-20 National University Of Singapore Focal adhesion kinase targeted therapeutics for the treatment of glaucoma and fibrosis
JP2021517589A (ja) 2018-03-12 2021-07-26 アンセルム（アンスティチュート・ナシオナル・ドゥ・ラ・サンテ・エ・ドゥ・ラ・ルシェルシュ・メディカル） 癌の治療のための化学免疫療法を増強するためのカロリー制限模倣物の使用
CN108912095B (zh) * 2018-08-09 2019-08-20 广州安岩仁医药科技有限公司 苯并咪唑类化合物及其制备方法和应用
US20220040317A1 (en) * 2018-09-27 2022-02-10 Dana-Farber Cancer Institute, Inc. Degradation of fak or fak and alk by conjugation of fak and alk inhibitors with e3 ligase ligands and methods of use
CN113387947B (zh) * 2021-07-12 2022-07-01 中国科学院成都生物研究所 调节雌激素受体合成活性的吡唑并吡啶衍生物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US166139A (en) * 1875-07-27 Improvement in dental pluggers
US6316603B1 (en) * 1998-09-08 2001-11-13 Agouron Pharmaceuticals, Inc. Modifications of the VEGF receptor-2 protein and methods of use
US7102009B2 (en) * 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
PL1660458T3 (pl) * 2003-08-15 2012-07-31 Novartis Ag 2,4-pirymidynodwuaminy stosowane w leczeniu chorób nowotworowych, chorób zapalnych i zaburzeń układu immunologicznego
GB0419160D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
GB0419161D0 (en) * 2004-08-27 2004-09-29 Novartis Ag Organic compounds
EP1746096A1 (en) * 2005-07-15 2007-01-24 4Sc Ag 2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
DK2134689T3 (da) * 2007-03-16 2014-06-30 Scripps Research Inst Inhibitorer af fokal adhæsionskinase
EP2249650A4 (en) * 2008-02-19 2012-01-11 Glaxosmithkline Llc ANILINOPYRIDINE AS A FAK HEMMER
JP5551689B2 (ja) * 2008-06-17 2014-07-16 アストラゼネカ アクチボラグ ピリジン化合物

Also Published As

Publication number Publication date
ZA201102892B (en) 2012-02-29
WO2010062578A1 (en) 2010-06-03
EP2421537A1 (en) 2012-02-29
EP2421537A4 (en) 2012-06-13
DK2421537T3 (da) 2015-06-22
BRPI0920053B8 (pt) 2021-05-25
SMT201500157B (it) 2015-09-07
AU2009320144A1 (en) 2010-06-03
AR073993A1 (es) 2010-12-15
CA2741760C (en) 2016-02-23
MX2011004369A (es) 2011-05-25
EP2421537B1 (en) 2015-04-08
JO3067B1 (ar) 2017-03-15
CO6361929A2 (es) 2012-01-20
MA32727B1 (fr) 2011-10-02
US20110269774A1 (en) 2011-11-03
SG195608A1 (en) 2013-12-30
ES2539835T3 (es) 2015-07-06
US9012479B2 (en) 2015-04-21
CN102264371B (zh) 2013-10-02
RS54045B1 (en) 2015-10-30
BRPI0920053B1 (pt) 2019-11-26
IL212444A0 (en) 2011-06-30
US9446034B2 (en) 2016-09-20
SI2421537T1 (sl) 2015-06-30
MY161890A (en) 2017-05-15
KR101512217B1 (ko) 2015-04-15
NZ592477A (en) 2013-01-25
CR20110264A (es) 2011-10-04
AU2009320144B2 (en) 2013-11-21
US20100113475A1 (en) 2010-05-06
CL2011000933A1 (es) 2011-10-21
PL2421537T3 (pl) 2015-08-31
JP5642689B2 (ja) 2014-12-17
TW201028394A (en) 2010-08-01
US20160095841A1 (en) 2016-04-07
PE20110941A1 (es) 2012-02-08
BRPI0920053A2 (pt) 2015-12-15
JP2012506876A (ja) 2012-03-22
DOP2011000113A (es) 2011-07-15
CN102264371A (zh) 2011-11-30
CA2741760A1 (en) 2010-06-03
UY32200A (es) 2010-05-31
US20150265589A1 (en) 2015-09-24
IL212444A (en) 2015-11-30
EA201170617A1 (ru) 2011-12-30
US20140107131A1 (en) 2014-04-17
HK1161680A1 (en) 2012-08-03
HRP20150531T1 (hr) 2015-06-19
TWI454467B (zh) 2014-10-01
EA021927B1 (ru) 2015-09-30
US20110207743A1 (en) 2011-08-25
KR20110080172A (ko) 2011-07-12
PT2421537E (pt) 2015-07-03

Similar Documents

Publication Publication Date Title
CY1116399T1 (el) Πυραζολυλαμινοπυριδινες ως αναστολεις της fak
CY1121792T1 (el) Ετεροκυκλικη ενωση
CY1121265T1 (el) Παραγωγα πιπεριδινονης ως αναστολεις της mdm2 για την θεραπευτικη αγωγη του καρκινου
CY1117078T1 (el) Παραγωγα 1-((5-ετεροαρυλθειαζολ-2-υλ) αμινοκαρβονυλ) πυρρολιδινο-2-καρβοξαμιδης ως αναστολεις φωσφατιδυλινοσιτολ 3-κινασης (ρι3κ) χρησιμα στη θεραπεια πολλαπλασιαστικων νοσων
CY1121854T1 (el) Αρυλoαζoλ-2-υλ κυανοαιθυλαμινο ενωσεις, μεθοδος κατασκευης και μεθοδος χρησης αυτων
CY1119534T1 (el) Παραγωγα φωσφορου ως αναστολεις κινασης
CY1118650T1 (el) Παραγωγα βενζιμιδαζολιου
CY1121364T1 (el) Νεοι κυτταροστατικοι νουκλεοζιτες 7-δεαζαπουρινης
CY1117200T1 (el) Παραγωγα βενζυλαμινης ως αναστολεις καλλικρεϊνης πλασματος
CY1111628T1 (el) Υποκατεστημενες ενωσεις δικυκλολακταμης
CY1117905T1 (el) Αναστολεις πρωτεϊνικης κινασης
CY1119422T1 (el) Παραγωγα μπετουλινης
CY1114764T1 (el) Παραγωγα προλινης ως αναστολεις καθεψινης
CY1117955T1 (el) Αμιδινο-υποκατεστημενες ενωσεις βητα-λακταμης, παρασκευη και χρηση τους ως αντιβακτηριακοι παραγοντες
CY1114500T1 (el) Γεφυρωμενα παραγωγα σπειρο[2.4]επτανιου ως αγωνιστες υποδοχεων alx kai/ή fprl2
CY1113486T1 (el) Συντηγμενες δικυκλικες πυριμιδινες
CY1116436T1 (el) Αλατα και πολυμορφα μιας ενωσης τετρακυκλινης
EA201290632A1 (ru) Производные бетулина
CY1117105T1 (el) Ενωσεις πυριδαζινονης και χρηση τους ως αναστολεις του daao
EA201170154A1 (ru) Производные пиридинопиридинонов, способ их получения и применение в терапии
CY1114354T1 (el) Νεα παραγωγα βενζαμιδιου ως ανταγωνιστες βραδυκινινης
CY1115729T1 (el) Τρικυκλικη ενωση και φαρμακευτικη χρηση αυτης
EA201190293A1 (ru) Пролекарства триптолида
CO6382123A2 (es) Antagonistas de la via hedgehog de ftalazina disustituida
CY1119872T1 (el) Παραγωγα τριαζινης προς χρηση σε μια επουλωτικη θεραπευτικη αγωγη